Common eye disease are cataracts, glaucoma, retinal disorders, and conjunctivitis.
Programs + Services
Ophthalmology (New England Eye Center) at Tufts Medical Center in Boston specializes in the testing and treatment of all types of eye diseases and visual problems.
More information about programs and services
Research + Clinical Trials
Age-related macular degeneration (AMD) is a disease that affects the retina, an integral part of the eye responsible for sensing light and relaying images to the brain. In the United States, AMD is the leading cause of irreversible vision loss as people age. Previous studies have shown that the nutrients lutein and zeaxanthin can help protect against AMD in middle aged and older adults. These nutrients form a pigment in the retina (macular pigment) that helps protect the retina from light damage. The more macular pigment in the retina, the better protection it offers.
Lutein and zeaxanthin are found in foods such as leafy green vegetables, broccoli, peas and avocados. They are also found in pistachio nuts, a bioavailable source of these nutrients. Since most people do not eat pistachio nuts daily, we are trying to see whether eating 2-ounces of pistachio nuts a day can help increase the density or amount of macular pigment in the eye.
More information about research and clinical trials
1. Men or women ≥18+ years of age with type 1 or 2 diabetes mellitus who have moderately severe to severe Non-proliferative Diabetic Retinopathy 2. Treatment-naïve (ie, no previous anti-VEGF or steroid treatment or PRP or laser within 1,000 μm of the foveal center/treatment for macular edema or DR in the study eye) 3. Willing and able to return for all study visits and comply with study-related procedures
More information about research and clinical trials
The study is being conducted to compare whether an optical correction of bifocal spectacle lenses (BFL) or single-vision spectacle lenses (SVL) is more effective for the treatment of children with esotropia greater at near. Children will be randomized to be treated with BFLs or SVLs for 3 years and be evaluated at regular intervals throughout the study to determine whether their condition has worsened. Children whose condition worsens during the study will either start BFL treatment (if randomized to SVL group) or continue BFL treatment (if randomized to BFL group) for 2 months to allow assessment of outcome in BFLs, and then be released to treatment at investigator discretion while continuing in study follow-up. Children whose condition has not worsened during the study will start or continue BFL (depending on treatment group) for 2 months at 3 years. All children return at 38 months to assess binocular function. The effectiveness and safety of both treatments will be compared.
More information about research and clinical trials
